VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

NA17.A2 Peptide Vaccine

Vaccine Information

Vaccine Name: NA17.A2 Peptide Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007093
Type: Peptide vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
MAGEA3 gene engineering:
- Type: Recombinant protein preparation
- Description: (Parmiani et al., 2014)
- Detailed Gene Information: Click Here.
MLANA gene engineering:
- Type: Recombinant protein preparation
- Description: (Parmiani et al., 2014)
- Detailed Gene Information: Click Here.
gp100 (PMEL) gene engineering:
- Type: Recombinant protein preparation
- Description: (Parmiani et al., 2014)
- Detailed Gene Information: Click Here.
Preparation: The vaccine included NA17.A2 clinical grade peptide or NA17.A2 combined with MAGE-3.A1 emulsified in Montanide ISA (Parmiani et al., 2014).
Description: This is for Melanoma Cancer(NCT01307618). A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas. (NCIT_C2680; Trakatelli et al., 2006)

Host Response

References

NCIT_C2680: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2680]

NCT01307618: [https://clinicaltrials.gov/ct2/show/NCT01307618?term=NA17.A2&rank=2]

Parmiani et al., 2014: Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology. 2014; 3(11); e963406. [PubMed: 25941591].

Trakatelli et al., 2006: Trakatelli M, Toungouz M, Blocklet D, Dodoo Y, Gordower L, Laporte M, Vereecken P, Sales F, Mortier L, Mazouz N, Lambermont M, Goldman S, Coulie P, Goldman M, Velu T. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer immunology, immunotherapy : CII. 2006; 55(4); 469-474. [PubMed: 16133111].